|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||25.83 - 26.51|
|52 Week Range||10.73 - 31.18|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.00|
The findings were enabled by Afirma® Xpression Atlas analyses, which uses RNA sequencing, of Veracyte’s extensive biorepository of thyroid nodule fine needle aspiration (FNA) samples from patients undergoing evaluation for thyroid cancer. The data were presented this week during the 89th Annual Meeting of the American Thyroid Association (ATA).
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
The new findings specifically show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. “Early lung cancer detection is key to saving lives.
“These data confirm the performance of our Percepta classifier and its ability to guide care for lung nodule patients when bronchoscopy findings are inconclusive,” said Bonnie H. Anderson, Veracyte’s chairman and chief executive officer. For the first study, researchers prospectively validated the Percepta GSC on a blinded, independent set of 412 samples from patients with lung nodules that were referred for bronchoscopy evaluation.
Specifically, the findings show that the Envisia classifier improves the performance of high-resolution CT (HRCT) imaging, which is typically used to help physicians distinguish IPF from other interstitial lung diseases (ILDs). “The new Envisia classifier data being presented at CHEST add to the growing body of evidence showing that the test complements HRCT and clinical factors for a more confident diagnosis,” said Bonnie H. Anderson, Veracyte’s chairman and chief executive officer.
How far off is Veracyte, Inc. (NASDAQ:VCYT) from its intrinsic value? Using the most recent financial data, we'll take...
Veracyte, Inc. today announced that it will release its financial results for the third quarter 2019 and business progress after the close of market on Tuesday, October 22, 2019.
Five Studies Reinforcing Clinical Performance and Utility of Company’s Marketed Genomic Tests in Lung Cancer and IPF Diagnosis Will Also Be Presented
Veracyte (VCYT) delivered earnings and revenue surprises of 44.44% and 3.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veracyte, Inc. today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m.
Veracyte, Inc. (VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC) available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the original Percepta test. The RNA whole-transcriptome sequencing-based test is Veracyte’s first commercial product to emerge since entering into the long-term strategic lung-cancer collaboration with Johnson & Johnson Innovation LLC*, which was announced in January 2019. “Lung nodules are often challenging to diagnose using traditional tools, which can lead to unnecessary invasive procedures or to delayed treatment,” said Giulia Kennedy, Ph.D., Veracyte’s chief scientific and medical officer.